Veeva Systems Inc. filings document formal disclosures for a Delaware public benefit corporation that sells industry cloud applications and data products to the life sciences sector. Recent Form 8-K reports furnish quarterly and annual operating results, announce material corporate events, and record capital actions including authorization of a Class A common stock repurchase program.
Proxy materials cover annual meeting votes, director elections, auditor ratification, board governance, and shareholder voting mechanics. Other current reports document officer succession and compensatory-arrangement matters, providing formal records of governance, leadership, capital structure, and financial-reporting updates for Veeva.
Schwenger Thomas D. reported acquisition or exercise transactions in this Form 4 filing.
Veeva Systems President & Chief Customer Officer Thomas D. Schwenger reported two grants of Restricted Stock Units (RSUs) linked to Class A common stock. The awards cover 11,628 and 14,535 underlying shares, representing equity compensation rather than open-market buying or selling.
According to the grant terms, one RSU award vests over one year, with one-quarter vesting on July 1, 2026 and the remainder vesting quarterly thereafter, subject to continued service. The second RSU award vests 100% on April 1, 2030, also contingent on continued service to the company.
Kondath Vipin reported acquisition or exercise transactions in this Form 4 filing.
Veeva Systems Chief Accounting Officer Vipin Kondath reported two grants of Restricted Stock Units (RSUs), each representing the right to receive one share of Class A Common Stock. One grant covers 669 RSUs, vesting over one year starting July 1, 2026, then quarterly, subject to continued service.
The second grant covers 5,884 RSUs, vesting 100% on April 1, 2030, also contingent on continued service with the company. These awards are compensation grants under Veeva’s Amended & Restated 2013 Equity Incentive Plan and are exempt from Section 16(b) under Rule 16b-6(b), not open-market stock purchases or sales.
Veeva Systems senior vice president, general counsel and secretary Jonathan Faddis received a grant of 6,541 Restricted Stock Units that can convert into an equal number of Class A common shares. The RSUs were granted under the company’s Amended & Restated 2013 Equity Incentive Plan as part of his compensation.
The award vests over one year, with 1/4 of the RSUs vesting on July 1, 2026, and the remaining RSUs vesting in equal quarterly installments thereafter, as long as he continues serving the company. Following this grant, Faddis holds 6,541 shares/units directly related to this award.
Veeva Systems Inc. Chief Financial Officer Brian Van Wagener reported routine equity compensation activity. On April 1, 2026, he exercised 872 Restricted Stock Units (RSUs), receiving an equal number of shares of Class A Common Stock at a price of $0.00 per share.
To cover tax obligations related to the RSU vesting, 370 shares of Class A Common Stock were withheld by Veeva at a price of $172.74 per share. This withholding was not an open-market sale but a tax payment mechanism. After these transactions, he directly held 8,383 shares of Class A Common Stock.
Veeva Systems executive Thomas D. Schwenger, Pres. & Chief Customer Officer, settled 2,043 Restricted Stock Units (RSUs) into an equal number of Class A Common shares on April 1, 2026. RSUs convert to stock at no cash cost to him.
To cover tax obligations from this vesting, 588 shares of Class A Common Stock were withheld by Veeva at $172.74 per share, a non-market, tax-withholding transaction. After these transactions, Schwenger directly holds 23,659 Class A shares of Veeva Systems.
Veeva Systems Chief Accounting Officer Vipin Kondath reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On April 1, 2026, RSUs covering 2,603 shares of Class A Common Stock were converted into shares, and 957 shares were withheld to satisfy tax obligations at $172.74 per share. After these transactions, Kondath directly held 2,676 shares of Class A Common Stock. The filing notes these events are exempt from Section 16(b) and that the tax-withholding entries are not market transactions.
Veeva Systems President & Chief of Staff Eleni Nitsa Zuppas exercised restricted stock units into Class A Common Stock and had shares withheld for taxes. On April 1, 2026, she converted RSUs into 8,998 shares of Class A Common Stock and 4,002 shares were withheld at $172.74 per share to cover tax obligations, which the company notes was not a market transaction. Following these transactions, she directly holds 31,238 shares of Class A Common Stock.
Veeva Systems SVP and General Counsel Jonathan Faddis exercised restricted stock units into Class A shares and had shares withheld for taxes. On April 1, 2026 he converted 7,500 and 1,226 RSUs into 8,726 shares of Class A Common Stock. The company withheld 3,370 and 440 shares, totaling 3,810 shares, at $172.74 per share to satisfy tax obligations, which is not a market sale. Following these transactions, he directly owns 8,525 shares of Class A Common Stock.
Veeva Systems Inc ownership update: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned representing 0% of common stock as of 03/13/2026. The filing states an internal realignment effective 01/12/2026 led certain Vanguard subsidiaries and business divisions to report ownership separately in reliance on SEC Release No. 34-39538.
Veeva Systems Inc. files its annual report describing a global provider of industry cloud software, data, and consulting for life sciences, from R&D through commercialization. The company operates as a Delaware public benefit corporation, aligning profit goals with a stated public benefit purpose.
Veeva organizes its offerings into Development, Quality, Commercial, and Data Clouds, enhanced by Veeva AI agents embedded in its Vault platform. As of January 31, 2026, it served 1,552 customers and employed 7,928 people worldwide.
The filing highlights key risks, including cybersecurity threats to sensitive clinical and patient data, intense competition from vendors such as Salesforce and IQVIA, challenges migrating CRM customers to Vault CRM, dependence on life sciences spending, expanding privacy and AI regulation, and reliance on third-party cloud providers.